Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by itntdfon Feb 07, 2023 11:29am
148 Views
Post# 35271865

RE:RE:RE:RE:Red Flags to Consider

RE:RE:RE:RE:Red Flags to Considernotable, sorry you don't appreciate the use of an analogy.  the agreement goes well beyond "intellectual property".  as the posted excerpts show, AN has an EXCLUSIVE right for the use of pela in their territory (subject to the terms of the agreement).

and as also posted, oncy currently has the rights to the "rest of the world".

AN paid $89 million, plus some milestone payments and an agreement to pay oncy(or subsequent purchaser of oncy) double digit royalties for the sale of licensed products in AN's territory.

for those considerations, AN secured the rights to pela (again, subject to the provisions of the agreement) for approximately 20% of the world's population.  can't imagine ANY scenario where AN just gets booted out or walks away without considerable compensation.

again, maybe you can find something in the agreement which explains your position but i don't think so.

seems like that is something pretty easy to understand.

can not find any language in the AN/ONCY agreement which has a termination provision giving oncy the right to just pull the rug out from under AN (in AN's exclusive territory).

would appreciate you posting a reference from the AN/ONCY agreement which would give a future buyer of ONCY the right to do that.
<< Previous
Bullboard Posts
Next >>